Apply Now

Eczema Research Study

Researchers at Stanford University School of Medicine are conducting a study to understand the causes of “red face” (head and neck eruptions) in patients using DUPIXENT® (dupilumab). They are also looking for people taking DUPIXENT® who don’t have this side effect to help with the study. The goal is to better understand the rash and find ways to treat and prevent it.

Apply Now

Fast Facts

Diagnosed With Eczema

Taking Dupilumab For Treatment Of Eczema

Compensation Provided

Conducted in San Francisco, CA

Study Background

Researchers at Stanford University are studying why some patients with atopic dermatitis (AD) who take DUPIXENT® (dupilumab) develop a skin condition called head and neck eruptions, or “red face.” This rash appears in some people using the medication, but the exact cause is not yet fully understood. The study will look at both patients who experience this rash and those who don’t to better understand what causes it.

The goal of this study is to figure out why some people get the rash while others don’t and to find ways to treat or prevent it. By understanding these causes, researchers hope to improve how DUPIXENT® is used and help patients with AD manage their treatment better.

 
Join our compensated study and contribute to atopic dermatitis research today! 

Study Background

Researchers at Stanford University are studying why some patients with atopic dermatitis (AD) who take DUPIXENT® (dupilumab) develop a skin condition called head and neck eruptions, or “red face.” This rash appears in some people using the medication, but the exact cause is not yet fully understood. The study will look at both patients who experience this rash and those who don’t to better understand what causes it.

The goal of this study is to figure out why some people get the rash while others don’t and to find ways to treat or prevent it. By understanding these causes, researchers hope to improve how DUPIXENT® is used and help patients with AD manage their treatment better.

 
Join our compensated study and contribute to atopic dermatitis research today! 
Apply Now

Additional Information

This study is being done to investigate the causes of “red face” (head and neck eruptions) in patients taking DUPIXENT® (dupilumab) and to find ways to treat and prevent this side effect. It also seeks to compare individuals with and without this rash to better understand the underlying processes.

You may qualify for a study if you meet the following criteria.

Inclusion Criteria:

  • Ages 18-65
  • Diagnosed with eczema
  • Currently taking Dupilumab for treatment of eczema
  • Not currently pregnant, breastfeeding, or planning to become pregnant
  • Known history of human immunodeficiency virus (HIV)
  • No known or suspected immunosupression

If you participate in the study, here’s what you can expect:

  1. Screening Visit: You will have an initial visit where you’ll be screened to see if you meet the study’s requirements.

  2. In-Person Visits (2 total): You will attend two visits at the Stanford Dermatology Clinic in Redwood City, CA. These can be completed on the same day.

  3. Virtual Visits (2 total): After the in-person visits, you’ll have two follow-up visits conducted virtually from the comfort of your home.

These visits will help researchers understand why some people taking DUPIXENT® develop “red face” (head and neck eruptions) and others do not.

Each participant will be paid $450 upon completion of the study.

There is no cost for you to participate in our research study.

Terms of Service

Privacy Policy

Terms of Service

Privacy Policy

Tagged